Connors Investor Services Inc. Acquires 65,479 Shares of Cellebrite DI Ltd. $CLBT

Connors Investor Services Inc. grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 36.3% during the 3rd quarter, Holdings Channel reports. The fund owned 245,789 shares of the company’s stock after buying an additional 65,479 shares during the period. Connors Investor Services Inc.’s holdings in Cellebrite DI were worth $4,554,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of CLBT. Invesco Ltd. grew its position in shares of Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after acquiring an additional 2,054,644 shares during the period. Voss Capital LP raised its holdings in Cellebrite DI by 34.0% in the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after purchasing an additional 1,306,398 shares during the period. Pertento Partners LLP lifted its position in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock valued at $86,131,000 after purchasing an additional 1,702,574 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its holdings in Cellebrite DI by 17.1% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock valued at $62,608,000 after purchasing an additional 570,000 shares during the period. Finally, Cooper Creek Partners Management LLC bought a new stake in Cellebrite DI during the third quarter valued at about $55,999,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Up 2.0%

NASDAQ CLBT opened at $14.69 on Wednesday. The stock’s 50 day moving average is $15.12 and its 200 day moving average is $16.88. Cellebrite DI Ltd. has a 12 month low of $11.76 and a 12 month high of $20.86. The stock has a market cap of $3.66 billion, a PE ratio of 47.39, a P/E/G ratio of 2.21 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.14. The business had revenue of $128.82 million during the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The company’s revenue was up 28.8% on a year-over-year basis. During the same period last year, the firm posted $0.10 EPS. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CLBT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Needham & Company LLC cut their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Finally, Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.